Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14873885 | 0.96 | DRD2 (0.55) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL22783652 | 0.93 | DRD2 (0.56) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL829612 | 0.92 | DRD2 (0.56) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL25128846 | 0.91 | DRD2 (0.51) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL24913972 | 0.90 | DRD2 (0.57) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL22783648 | 0.88 | DRD2 (0.52) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL513795 | 0.87 | MEN1 (0.55) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL13609474 | 0.87 | DRD2 (0.60) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL31301221 | 0.86 | DRD2 (0.55) | DRD2SIGMAR1TDP1MEN1KMT2A | |
| SCHEMBL8254760 | 0.85 | DRD2 (0.64) | DRD2SIGMAR1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909948-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2024-02-28 | — | — | EP | disclosed |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-05-12 | — | — | US | disclosed |
| US-11266754-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-03-08 | — | — | US | disclosed |
| EP-3909948-A1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3227272-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2021-07-07 | — | — | EP | disclosed |
| US-20200038527-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-02-06 | — | — | US | disclosed |
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-11-16 | — | — | US | disclosed |
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-11-16 | — | — | US | disclosed |
| WO-2016087667-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
| EP-3029032-A1 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | Centre National de la Recherche Scientifique (CNRS) (FR) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038527-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | DRD2 176/4885SIGMAR1 271/4885TDP1 2690/4885 |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | DRD2 176/4885SIGMAR1 271/4885TDP1 2690/4885 |
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | DRD2 176/4885SIGMAR1 271/4885TDP1 2690/4885 |
| US-11266754-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | AP2A2, ATP2A2, SLC20A2 | DRD2 176/4885SIGMAR1 271/4885TDP1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.